Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses

At a J.P. Morgan Healthcare Conference on Monday, Amgen Inc.(NASDAQ:AMGN) CEO Robert Bradway shared findings from part 2 of the Phase 2 Study of MariTide, its investigational obesity treatment. • Amgen stock is showing positive momentum. What’s the outlook for AMGN shares?Key FindingsThe large majority of participants maintained the weight loss achieved in part 1 for an additional 52 weeks on a lower monthly dose or quarterly dose of MariTide.The second year of MariTide treatment was very well tolerated, in ...